Oculis (NASDAQ:OCS) Sees Large Volume Increase – What’s Next?

Shares of Oculis Holding AG (NASDAQ:OCS) saw unusually-high trading volume on Friday . Approximately 1,115,990 shares traded hands during mid-day trading, an increase of 212% from the previous session’s volume of 357,595 shares.The stock last traded at $23.4510 and had previously closed at $29.65.

Wall Street Analyst Weigh In

OCS has been the topic of several research reports. HC Wainwright boosted their price target on shares of Oculis from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. JPMorgan Chase & Co. boosted their price target on shares of Oculis from $38.00 to $42.00 and gave the stock an “overweight” rating in a research report on Monday, May 18th. Stifel Nicolaus boosted their price target on shares of Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Guggenheim initiated coverage on shares of Oculis in a research report on Wednesday, May 20th. They issued a “buy” rating and a $75.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.38.

Oculis Price Performance

The stock has a 50 day moving average of $27.68 and a two-hundred day moving average of $25.17. The stock has a market cap of $1.32 billion, a PE ratio of -10.66 and a beta of 0.38. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The company had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. Equities analysts anticipate that Oculis Holding AG will post -2.21 EPS for the current year.

Hedge Funds Weigh In On Oculis

Institutional investors have recently bought and sold shares of the stock. Gildi lifeyrissjodur purchased a new position in Oculis in the 4th quarter worth about $50,250,000. Aberdeen Group plc increased its stake in Oculis by 39.4% in the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after purchasing an additional 493,827 shares in the last quarter. Syquant Capital Sas purchased a new position in Oculis in the 4th quarter worth about $3,849,000. Simplify Asset Management Inc. purchased a new position in Oculis in the 4th quarter worth about $1,972,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after purchasing an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.